Special Issue "Cancer Drug Resistance"

Quicklinks

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (30 June 2014)

Special Issue Editor

Guest Editor
Dr. Xiaolong He
Department of Biopharmaceutical Sciences, College of Pharmacy and Cancer Center, University of Illinois at Chicago, Chicago, IL 60612, USA
Website: http://www.uic.edu/pharmacy/depts/Biopharmaceutical_Sciences/our_people/faculty/he.php
E-Mail: xiaohe@uic.edu
Phone: +1 815 395 5929
Interests: multidrug resistance; ABC transporters; tumorigenesis; targeted therapy; alternative splicing; cancer stem cells; gene targeting; biomarkers

Special Issue Information

Dear Colleagues,

Drug resistance represents a major obstacle to the success of cancer treatments. Drug resistance occurs not only with classical chemotherapeutics, but also with more recent, molecularly-targeted therapies. A variety of molecular mechanisms have been implicated in the development of resistance; these mechanisms include increased drug efflux, altered drug metabolism, mutated or amplified drug targets, enhanced compensatory signaling pathways, etc.

Modern technologies in genomics, proteomics, and epigenomics have made it possible to dissect the molecular changes underlying drug resistance in an unprecedentedly detailed and comprehensive manner. The current challenge is to identify clinically meaningful biomarkers from these “-omics” studies so as to predict individual patients' responses to particular drugs and devise drug combinations to overcome or prevent potential resistance. This Special Issue is devoted to publishing original research reports and review articles that concern drug resistance in cancer treatment. The topics can be, but are not limited to the following:

  • High-throughput analysis of drug-sensitive and resistant human tumors
  • Epigenetic changes in drug-resistant cancer cells
  • microRNAs in the development of cancer drug resistance
  • Biomarkers for prediction of drug response
  • ABC transporters in drug resistance
  • Tumor heterogeneity and drug resistance
  • Treatment of resistant cancer cells

Dr. Xiaolong He
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 800 CHF (Swiss Francs).

Keywords

  • cancer drug resistance
  • chemotherapy
  • targeted therapy
  • biomarkers
  • microarray
  • microRNA
  • ABC transporters
  • high-throughput analysis

Published Papers (5 papers)

Download All Papers
Sort by:
Display options:
Select articles Export citation of selected articles as:
Select/unselect all
Displaying article 1-5
p. 2137-2154
by , , , , , , ,  and
Cancers 2014, 6(4), 2137-2154; doi:10.3390/cancers6042137
Received: 29 April 2014; in revised form: 8 September 2014 / Accepted: 24 September 2014 / Published: 21 October 2014
Show/Hide Abstract | PDF Full-text (633 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Drug Resistance)
p. 2035-2048
by , , , , ,  and
Cancers 2014, 6(4), 2035-2048; doi:10.3390/cancers6042035
Received: 28 June 2014; in revised form: 21 August 2014 / Accepted: 15 September 2014 / Published: 30 September 2014
Show/Hide Abstract | PDF Full-text (546 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Drug Resistance)
p. 1925-1952
by , ,  and
Cancers 2014, 6(4), 1925-1952; doi:10.3390/cancers6041925
Received: 31 July 2014; in revised form: 4 September 2014 / Accepted: 11 September 2014 / Published: 29 September 2014
Show/Hide Abstract | PDF Full-text (1544 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Drug Resistance)
p. 1769-1792
by , , , , ,  and
Cancers 2014, 6(3), 1769-1792; doi:10.3390/cancers6031769
Received: 15 July 2014; in revised form: 25 August 2014 / Accepted: 29 August 2014 / Published: 5 September 2014
Show/Hide Abstract | PDF Full-text (427 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Drug Resistance)
p. 1753-1768
by , , , , , , , , , ,  and
Cancers 2014, 6(3), 1753-1768; doi:10.3390/cancers6031753
Received: 21 February 2014; in revised form: 8 August 2014 / Accepted: 11 August 2014 / Published: 29 August 2014
Show/Hide Abstract | PDF Full-text (1169 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Drug Resistance)
Select/unselect all
Displaying article 1-5
Select articles Export citation of selected articles as:

Last update: 3 January 2014

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert